GHK-Cu Dosing & Administration Protocol

Comprehensive dosing reference for GHK-Cu — covering topical concentrations and vehicles, subcutaneous injection protocols, reconstitution calculations, storage conditions, cycle lengths, and safety considerations. All information compiled from published literature and established research protocols.

Dosing by Administration Route

Dosing information compiled from published literature and community protocols. Human clinical dosing is established primarily for topical use. Injectable protocols are derived from preclinical data and anecdotal research experience. For informational purposes only.

Topical Application

Best-established route — clinical evidence
Concentration0.01% – 1% w/v
Frequency1 – 2× daily
ApplicationClean skin, affected area
VehicleCream, serum, or solution
Best ForSkin, wound healing, hair
Evidence LevelClinical trials available

Subcutaneous Injection

Systemic research protocol
Typical Dose200 – 500 mcg/day
Frequency1× daily
Injection SiteAbdominal subcutaneous
ReconstitutionBacteriostatic water
Cycle Length4 – 12 weeks
StorageRefrigerate reconstituted

Reconstitution Guide

Injectable preparation
Vial SizeTypically 5 mg lyophilized
Add BAC Water2 mL → 2.5 mg/mL
200 mcg Dose= 0.08 mL (8 units)
500 mcg Dose= 0.2 mL (20 units)
Shelf Life~28 days refrigerated
Needle Gauge29 – 31G insulin syringe

Protocol by Research Goal

Skin Anti-Aging

Topical — face & neck
Concentration0.01% – 0.1%
FrequencyAM + PM
VehicleSerum or light cream
Duration8 – 16 weeks
Stack WithVitamin C (AM), Retinol (PM)

Wound Healing

Topical — wound bed
Concentration0.1% – 1%
Frequency1 – 2× daily
VehicleHydrogel or cream
DurationUntil healed
Stack WithStandard wound care

Hair Growth

Topical — scalp
Concentration0.1% – 0.5%
Frequency1 – 2× daily
VehicleEtOH/PG solution
Duration3 – 6 months
Stack WithMinoxidil (separate)

Reconstitution Step-by-Step

Materials Required

To reconstitute lyophilized GHK-Cu powder for subcutaneous injection, you will need: bacteriostatic water (BAC water, not sterile water — BAC water contains benzyl alcohol preservative to extend shelf life), insulin syringes (29–31G, 0.3–1 mL), alcohol swabs, and the lyophilized GHK-Cu vial. Verify the vial is sealed and the powder is white/off-white and dry before proceeding.

Reconstitution Steps

1. Swab the rubber stopper of the GHK-Cu vial and the BAC water vial with an alcohol swab. Allow to dry for 10 seconds.
2. Draw the desired volume of BAC water into your syringe. For a 5 mg vial, draw 2 mL of BAC water to achieve a concentration of 2.5 mg/mL (2,500 mcg/mL).
3. Inject the BAC water slowly into the GHK-Cu vial by directing the stream down the side of the glass (not onto the powder directly), to minimize foaming.
4. Gently swirl — do not shake — until the powder is fully dissolved. The solution should be clear to slightly blue-tinted (the copper chelate gives it a faint color).
5. Label the vial with the date of reconstitution. Store refrigerated (2–8°C). Use within 28 days.

Dosing Calculations (2.5 mg/mL stock)

100 mcg dose = 0.04 mL = 4 units on a U-100 insulin syringe
200 mcg dose = 0.08 mL = 8 units on a U-100 insulin syringe
300 mcg dose = 0.12 mL = 12 units on a U-100 insulin syringe
500 mcg dose = 0.20 mL = 20 units on a U-100 insulin syringe

If using a different vial size or BAC water volume, adjust accordingly: concentration (mcg/mL) = (vial mass in mcg) ÷ (BAC water volume in mL).

Injection Technique

Subcutaneous injection sites include the abdomen (2 inches from the navel), outer thigh, and upper arm. Pinch the skin, insert the needle at a 45–90° angle, inject slowly, and withdraw. Rotate injection sites to avoid localized tissue irritation. GHK-Cu is generally well tolerated subcutaneously with minimal injection site reactions reported.

Safety & Tolerability

GHK-Cu has a long safety record in topical cosmetic applications and has been used in FDA-cleared wound dressings. Injectable safety data is more limited.

🟢 Established Safety Data

  • Decades of safe topical use in skincare at concentrations up to 1% — well tolerated across skin types
  • GHK-Cu has been incorporated into FDA-cleared wound care products (copper-peptide wound dressings)
  • Naturally present in human plasma — not a xenobiotic compound; physiological familiarity reduces immunogenic risk
  • No mutagenic activity detected in Ames testing or in vitro genotoxicity assays
  • Clinical studies report no significant adverse events with topical application over multi-week protocols
  • Favorable copper delivery profile — GHK releases Cu²⁺ at physiological rates, avoiding copper toxicity risks associated with inorganic copper salts

⚠️ Important Considerations

  • Injectable use lacks large-scale human clinical trials — most injectable data is preclinical or anecdotal
  • Individuals with Wilson's disease or other copper metabolism disorders should avoid GHK-Cu entirely
  • Theoretical concern: pro-angiogenic effects could support tumor vascularization in individuals with pre-existing malignancies
  • Excessive copper intake (from multiple supplemental sources combined with GHK-Cu) could theoretically contribute to copper overload
  • Quality and purity of sourced GHK-Cu peptide varies — always require third-party COA with HPLC and MS verification
  • GHK-Cu is not FDA-approved as an injectable drug — regulatory status is as a research peptide and cosmetic ingredient

Explore More GHK-Cu Research

⚠ Research Use Disclaimer

GHK-Cu is sold as a research compound and cosmetic ingredient. Injectable forms are not approved by the FDA or any regulatory agency for human therapeutic use. Topical GHK-Cu is used in cosmetic products and FDA-cleared wound dressings but is not classified as a drug. The information on this page is compiled from published peer-reviewed research and is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any health decisions.